Related Experiment Video
Updated: Sep 13, 2025
10:11
Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
36.4K
Development of a Novel, Highly Sensitive System for Evaluating Ebola Virus Particle Formation
Wakako Furuyama1, Miako Sakaguchi2, Hanako Ariyoshi1
1National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki 852-8523, Japan.
Viruses
|July 30, 2025
Summary
A new screening system detects Ebola virus VP40 protein release, aiding the development of antivirals targeting viral particle formation. This method is crucial for finding new treatments against Ebola virus and similar filoviruses.
Area of Science:
- Virology
- Molecular Biology
- Drug Discovery
Background:
- Ebola virus (EBOV) causes severe hemorrhagic fevers with limited treatments.
- The EBOV VP40 protein is critical for viral assembly and release, making it a key drug target.
- No current drugs target the viral particle formation process.
Purpose of the Study:
- To develop a sensitive screening system for evaluating VP40-mediated virus-like particle (VLP) formation.
- To facilitate the discovery of novel antiviral agents targeting late-stage EBOV infection.
Main Methods:
- Established a biosafety level-2 screening system using a HiBiT luminescence reporter fused to VP40.
- Validated the system by assessing Rab11-dependent trafficking and the effect of nocodazole on VLP release.
Main Results:
- The N-terminally fused HiBiT-VP40 (N) construct effectively forms VLPs, serving as a functional reporter.
- The screening system successfully detected VP40 release and VLP formation.
- Rab11-dependent trafficking and microtubule dynamics were confirmed to influence VP40-mediated budding.
Conclusions:
- A novel, sensitive, and reliable screening platform for identifying inhibitors of EBOV particle formation and release has been developed.
- This system is adaptable for screening against other filoviruses, broadening its therapeutic potential.
- The findings support targeting VP40 for antiviral drug development against filoviral infections.
